Vasoactive agents which elevate either cGMP or cAMP inhibit platelet activation by pathways sharing at least one component, the 46/50 kDa vasodilator-stimulated phosphoprotein (V ASP). V ASP is stoichiometrically phosphorylated by both cGMP-dependent and cAMPdependent protein kinases in intact human platelets, and its phosphorylation correlates very well with platelet inhibition caused by cGMP-and cAMP-elevating agents.
Introduction
Numerous vasoactive agents regulate human platelet activation. Platelet agonists such as thrombin, thromboxane A z , platelet activating factor, collagen and ADP elevate intracellular free Ca2+, activate myosin light chain kinase, protein kinase C and protein tyrosine kinases, and platelet activation ultimately results in shape change, adhesion, aggregation and degranulation (Haslam, 1987; Siess, 1989; Rink and Sage, 1990) . In contrast, many physiologically and pharmacologically important platelet inhibitors such as prostacyclin and endothelium-derived relaxing factor (EDRF) elevate platelet levels of cAMP, cGMP or both , activate cAMP-and/or cGMP-dependent protein kinases (cAMP-PK, cGMP-PK) and inhibit platelet activation by agonists (Walter, 1989; Walter et al., 1991) . The two cyclic nucleotides cAMP and cGMP may have distinct but also © Oxford University Press common sites of action in human platelets. Cyclic nucleotideinduced inhibition of platelet activation apparently involves an early step of the activation cascade such as inhibition of phospholipase C and subsequent Ca2+ discharge from intracellular stores (Siess, 1989; Rink and Sage, 1990; WaIter et al., 1991; Geiger et al., 1992) . Alternatively, Caz +-ATPases, myosin light chain kinase (Walter, 1989; WaIter et al., 1991) and cytoskeletal elements (Fox, 1987; Zhang et al., 1988; Chen and Stracher, 1989; Fox and Berndt, 1989; Siess, 1989) have also been considered as potential targets , but the precise mechanism of action of cyclic nucleotide-elevating platelet inhibitors is not very well understood.
Recently, we purified and characterized a 46/50 kDa vasodilator-stimulated phosphoprotein (V ASP) which is stoichiometrically phosphorylated by cAMP-or cGMPdependent protein kinase in experiments with purified proteins as well as in intact human platelets treated with cAMP-or cGMP-elevating platelet inhibitors, respectively (Waldmann et al., 1986 (Waldmann et al., , 1987 Halbriigge and Walter, 1989; . VASP phosphorylation at one site by either protein kinase alters the properties of the protein in SOS -PAGE causing a shift in its apparent molecular mass from 46 to 50 kDa (Halbriigge and Waiter, 1989) . This phosphorylation-induced change in the apparent molecular mass of V ASP has recently been used for the quantitative analysis ofVASP phosphorylation in intact cells Nolte et al., 199Ia,b) .
V ASP phosphorylation correlates very well with vasodilator-induced inhibition of platelet activation (Waldmann et al., 1987; Siess and Lapetina, 1990; WaIter et al., 1991) ; however, the precise functional role of V ASP has not been elucidated. Recently, the presence and regulation of V ASP phosphorylation was also discovered in other human cell types including Iymphocytes and granulocytes (Halbriigge et al., 1992) . Because of the potential importance of this 46/50 kDa phosphoprotein V ASP for signal transduction pathways regulated by both cAMP-and cGMP-elevating hormones and vasoactive agents , we have now investigated the subcellular distribution of V ASP in human platelets and a variety of other cell types. Evidence will be presented that V ASP is a novel phosphoprotein associated with actin filaments and focal contact areas. Our data suggest these cellular structures and their associated proteins as potential targets for regulation by cAMP-and cGMP-dependent protein kinases .
Results

Characterization of VASP antiserum M4
In immunoblots of platelet and fibroblast homogenates, a polyclonal rabbit antiserum raised against purified V ASP (M4) specifically recognized a polypeptide doublet of 46/50 kDa ( Figure 1, lanes 3-4) . The 46 kDa VASP shifts to a protein with apparent molecular mass of 50 kDa in SOS -PAGE when one specific site is phosphorylated by cAMP-or cGMP-dependent protein kinases (Halbriigge and Walter, 1989) . Thus, the 46 kDa and 50 kDa protein bands recognized by antiserum M4 represent dephospho-and phosphoforms of V ASP with respect to this particular phosphorylation site and will subsequently be referred to as dephospho-and phospho-V ASP, respectively , although V ASP contains additional phosphorylation sites which were not analysed here. Imrnunoblotting experiments with antiserum M4 and affinitypurified M4 gave identical results (Figure 1, lanes 1, 3 and  4) . Moreover, the patterns of subcellular V ASP distribution obtained by immunofluorescence were identical with antiserum M4 and affinity-purified M4, whereas preimmune serum was negative (not shown). When affinity-purified M4 was preincubated with the 46/50 kOa area of nitrocellulose sheets to which platelet homogenate proteins had been transferred after SOS -PAGE, its V ASP-staining capacity was completely lost as assayed by immunoblots ( Figure 1 , lane 2) or by indirect immunofluorescence (not shown) . These results demonstrated that M4, used as complete serum or after affinity purification, selectively recognized V ASP in its SOS-denatured form as well as in situ .
Localization of VASP to microfilaments and focal contact areas
Platelets that are allowed to settle onto coverslips adhere and begin to extrude pseudopods (Zobel and Woods, 1983; Behnke and Bray, 1988) . These pseudopods have been shown to contain microfilament bundles (Debus et al., 1981) and their distal portions coincide with areas of firm 2064 attachment to the underlying substratum (focal contacts; Zobel and Woods, 1983; Alexandrova and Vasiliev , 1984) . Staining of spreading and fully spread platelets for actin shows three main areas of fluorescence , i.e. the radial microfIlament bundles, the rim of the veil-like lamellae spread out between such bundles (Oebus et al. , 1981 ; Figure 2a ' -e'), and , in some platelets, a ring-like structure in the centre of the platelet (Figure 2e' ) . Indirect immunofluorescence with antiserum M4 showed V ASP concentrated in two of these structures, the terminal portions of radial micro filament bundles and the peripheral microfilaments of veils (Figure 2a -e) . The central ring, which in fully spread platelets appeared as an area of very prominent actin staining, was labelled less intensely and less homogeneously with M4, revealing a dotted distribution of V ASP (Figure 2e and e').
M4 also revealed the expression and subcellular distribution of V ASP in tissue culture cells. In analogy to the staining patterns of adhering platelets, V ASP appeared to be highly concentrated at the terminal portions of microftlament bundles (stress fibres) of stationary fibroblasts derived from man or rat , respectively , and also at the peripheral regions of the protruding lamellae developed by locomoting or spreading cells, especially in ruffling areas (Figure 3d ). In addition, well spread fibroblasts showed a distinct, quite regular distribution of V ASP as periodically arranged dots along their stress fibres ( Figure 3a , e and t) .
Expression of VASP in different cell types
The expression of V ASP was analysed by immunoblotting of homogenates from different blood and tissue culture cells and also by indirect immunofluorescence (Table I) . With regard to human cells, V ASP was found not only in platelets and differentiated blood cells like granulocytes and lymphocytes, but also in their tumour derivatives, leukaemia (HEL 92 .1.7, HL-60 and K -562) and lymphoblastoma (HuT 78 , Jurkat, Raji and U-937) cells. V ASP was also located in certain tissue-forming cells analysed (endothelial cells, vascular smooth muscle cells and fibroblasts) and in cell lines derived from such cells (neuroblastoma -glioma hybrid cells N x G 108CC15 and epithelial cells A-431, LLC-PK1 , BHK and PtK2). In addition , prominent VASP staining was detected at the site of intercalated discs of rat heart (data not shown) .
Although the content of V ASP in different cells has not been exactly quantified, a rough estimate derived from a comparison of lanes 3 and 4 in Figure 1 suggests that there is -5-to 8-fold more V ASP per mg of homogenate in platelets than in human dermal fibroblasts . Platelets have been shown previously to contain 2.45 p,g/mg VASP (Halbriigge and Waiter , 1990) . Like fibroblasts , other cell types of human origin so far investigated contained less VASP than platelets (Halbriigge et al., 1992) .
Phosphorylation of VASP in intact human fibroblasts in response to prostaglandin E1 (PG-E 1 ) and a cGMPanalogue
The demonstration of V ASP as part of the microfIlamentous system not only in platelets but also in fib rob lasts raised the question of whether V ASP is phosphorylated by cAMP-and cGMP-dependent protein kinases in intact fibroblasts , as has already been demonstrated for platelets (Waldmann et al., 1987; . Therefore, the state ofVASP phosphorylation was determined in homogenates of human dermal fibroblasts which had been incubated with either PGEl or with 8-(4-chlorophenylthio)-guanosine-3' ,5'cyclic monophosphate (8-pCPT -cGMP). PG-El was chosen since this prostaglandin raises cAMP in many cell types including fibroblasts (Smith, 1989) and causes VASP phosphorylation mediated by cAMP-PK in platelets and lymphocytes (Halbriigge et al., , 1992 . 8-pCPT-cGMP was chosen since this cell membrane permeant cGMP-analogue is a selective cGMP-PK activator which has no major effects on other protein kinases or phosphodiesterases and which was shown to cause V ASP phosphorylation mediated by cGMP-PK in platelets (Geiger et al., 1992) . After a 5 min incubation of fibroblasts with 5 JLM PG-Eh almost all of V ASP was converted from the 46 kDa dephosphoform to the 50 kDa phosphoform, whereas a 30 min incubation with 8-pCPT -cGMP shifted about half of V ASP to its 50 kDa phosphoform (Figure 4 ). Incubation with a combination of PG-El and 8-pCPT-cGMP was no more effective than PGEl alone (Figure 4) . The fluorescence analysis of VASP distribution and actin organization did not reveal any dramatic differences between controls and cells treated with either PG-E) or 8-pCPT-cGMP (not shown). Also, conditions which affected the phosphorylation state of V ASP 2066 (e.g. treatment of cells with PG-E) and 8-pCPT-cGMP) did not alter the Triton X-lOO solubility of VASP since VASP was recovered nearly quantitatively in the soluble fraction of both control and treated cells (not shown). 
Cosedimentation of VASP with F-actin
The co-localization of V ASP with microfilaments, as revealed by indirect immunofluorescence, prompted the question of whether V ASP binds directly to F-actin . To address this question, purified V ASP and F-actin were coProtein associated with actin filaments and focal contacts . Binding of V ASP to F-actin in a cosedimentation assay. V ASP and F-actin were mixed (final concentrations: 110 I'g/ml VASP, 500 I'g/ml actin), incubated for 30 min at room temperature and then centrifuged at 100 000 g for 2 h. Equivalent amounts of supernatants (S) and resuspended pellets (P) were separated by SDS -PAGE and stained with Coomassie blue. The composition of the samples analysed is indicated at the top of each lane. incubated for 30 min at room temperature, and the mixture was subsequently centrifuged at 100 000 g for 2 h. F-Actin was pelleted nearly quantitatively by this high speed centrifugation, and a major part of total VASP co-sedimented with F-actin, whereas in the absence of F-actin no VASP was detected in the 'pellet' fraction ( Figure 5) . Interestingly, the ratio of the 46 kDa and 50 kDa forms of V ASP found in the F-actin pellet was similar to that found in the supernatant (Figure 5 ), suggesting that both the 46 and 50 kDa forms of V ASP cosedimented equally well with F-actin, It is unlikely that the cosedimentation of actin and V ASP was due to contaminating proteins since the preparations of both actin and V ASP were > 95 % pure and since no contaminating proteins (which could have mediated V ASP binding to F-actin) were observed in the pellet fractions when analysed by SDS-PAGE and Coomassie blue staining ( Figure 5 ), However, our findings do not exclude the possibility that, in cells, the association of V ASP with actin filaments is mediated by an interaction with other components,
Discussion
VASP is a novel actin filament-and focal contactassociated protein
The results of this study together with our published biochemical data indicate that V ASP, a substrate for cAMPas well as cGMP-dependent protein kinases, is a widely distributed, novel protein associated with actin fIlaments and focal contact areas, Many actin-binding proteins have already been described (Vandekerckhove, 1990; Hartwig and Kwiatkowski, 1991) , some of which have an apparent molecular mass similar to that of V ASP in SDS -PAGE. Therefore, it has to be considered whether V ASP may be identical to one of these or related proteins, in particular tropomodulin, band 4,9 or a 53 kDa actin fIlament bundling protein from porcine brain. In contrast to V ASP, tropomodulin is not a substrate for cAMP-PK (Fowler, 1987) , nor does it bind to F-actin (Fowler, 1990) . VASP and band 4.9 differ with respect to their Triton X-lOO solubility (this study ; Faquin et al., 1988) and their properties as protein kinase C substrates (Home et al., 1985 ; Palfrey and Waseem, 1985; Faquin et al., 1986 Faquin et al., , 1988 Waldmann et al. , 1987) . Furthermore, the hydrodynamic properties of V ASP indicate a highly asymmetrical structure (unpublished results) and differ from the hydrodynamic properties reported for tropomodulin (Fowler, 1987) , band 4.9 (Siegel and Branton, 1985) and the 53 kDa actin ftlament bundling protein from porcine brain (Maekawa et al., 1983) . Sasaki et al. (1990) purified a 48 kDa protein from platelets which bound to an actin -Sepharose column; however, the limited data available on this protein do not allow a direct comparison with V ASP.
Our recent, unpublished data strongly indicate that V ASP differs not only from biochemically characterized actin ftiament-and focal contact-associated proteins, but also from all proteins with established primary structure. Comparison of partial V ASP sequences (obtained from protein microsequences and a partial cDNA clone) to sequences currently available in nucleic acid and protein databases , revealed no identity with any protein (C.Haffner et al., unpublished results), including the 47 kDa N-terminal proteolytic fragment of talin (Rees et al., 1990) .
The immunofluorescence analyses reported here demonstrate that V ASP is associated with the microfilament system of a wide variety of cell types. Like VASP, several other microfilament proteins such as talin (Burridge and Connell, 1983a,b) and a-actinin (Lazarides and Burridge, 1975) were also found to be concentrated at focal adhesion sites , i.e. at cell-matrix junctions , and in the cortical actin filament webs at the periphery of highly dynamic lamellae. VASP is also present in cell-cell contacts (unpublished). This concentration in cell-matrix as well as in cell-cell junctions, together with the distinct and periodical localization of V ASP in stress fibres (which contain microfilament proteins arranged in sarcomere-like units) is especially reminescent of the distribution of a-actinin. Indeed , we found that these V ASP-positive spots, like aactinin (Sanger et al., 1983) , showed a cell-line specific spacing, and double labelling with antibodies against V ASP and a-actinin produced superimposable patterns of immunofluorescence (unpublished observations) . However, there are also differences in the intracellular localization of these two proteins. In particular, the intracellular localization of V ASP in spread platelets (this study) differs from that of a-actinin (Debus et al., 1981) , and V ASP is not associated with the cleavage furrow in mitotic cells or with the peripheral belt of epithelial cells (unpublished), whereas all these structures have been found to contain a-actinin (Fujiwara et al., 1978; Sanger et al., 1987; Schulze et al ., 1989) .
Phosphorylation of VASP by cAMP-and cGMPdependent protein kinases in fibroblasts
Analysis of the phosphorylation-induced change in V ASP mobility in SDS -PAGE was used to determine the state of V ASP phosphorylation in intact human fibroblasts . In addition , the effects of agents which have been shown Geiger et al., 1992) to activate 2068 selectively either cAMP-PK (e.g. PG-El) or cGMP-PK (e .g. 8-pCPT-cGMP) were analysed. As demonstrated in Figure 4 , activation of cAMP-PK by PG-El converted V ASP almost quantitatively from the 46 kDa dephosphoform to the 50 kDa phosphoform, whereas maximal V ASP phosphorylation due to activation of cGMP-PK by 8-pCPTcGMP was -50%. These data not only demonstrate V ASP phosphorylation in intact fib rob lasts , but also provide functional evidence for the presence and regulation of cGMP-PK in these cells. The latter is not trivial since the limited expression and cellular distribution of cGMP-PK, as well as low cellular concentrations of cGMP-PK, have hindered investigations of the physiological role of this kinase (Walter, 1989) . Only preliminary immunocytochemical experiments (Walter, 1989) had suggested that fibroblasts may contain type I cGMP-PK .
Appropriate elevation of cAMP-PK activity in fibroblasts and epithelial cells is known to result in reversible disruption of stress fibres (Lamb et al. , 1988; Roger et al., 1988; Turner et at. , 1989) and in the loss of talin and vinculin from focal contacts (Turner et al., 1989) . The phosphorylation and concomitant inhibition of myosin light chain kinase by cAMP-PK is thought to be of fundamental importance for the observed breakdown of the cellular actin skeleton (Lamb et al., 1988; Fernandez et al., 1990) . However, the cAMP-PK-mediated phosphorylation of VASP in fibroblasts described in this study is nearly quantitative and complete after a 5 min incubation with PG-El , i.e. under conditions where major alterations of the actin skeleton are not detectable. Also, cGMP-PK-mediated V ASP phosphorylation was not accompanied by gross morphological alterations in the cells studied.
Alternatively, V ASP phosphorylation may have functional consequences other than structural changes of the actin cytoskeleton. Cyclic nucleotide elevating agents which stimulate V ASP phosphorylation in human platelets concomitantly inhibit both the protein kinases (myosin light chain kinase and protein kinase C) and the Ca2+ mobilization associated with platelet activation (Waldmann et al., 1987; Waiter, 1989; Nolte et al., 1991a,b; Geiger et al. , 1992) . This multifocal inhibition would be easiest to achieve if phospho-V ASP inhibited an early step of platelet activation, e .g . at the level of phospholipase C (WaIter, 1989; WaIter et al., 1991 ; Geiger et al., 1992) . Furthermore, our present evidence demonstrating a cytoskeletal association of V ASP would position V ASP at a site which is perhaps critical for regulation of phospholipase C. Recently , thrombin activation of platelets was shown to increase the total cytoskeleton associated enzyme activities of phospholipase C, inositollipid kinases and diacylglycerol kinase (Grondin et al., 1991) . A similar cytoskeleton association and regulation of such enzyme activities involved in lipid metabolism has been reported for EGF-treated A-431 cells (Payrastre et al., 1991) . Therefore, the cytoskeleton, and in particular cytoskeleton anchorage sites at the plasma membrane, are prominent candidates for forming a matrix for close contacts between various signal transduction components (Grondin et al., 1991 ; Payrastre et al. , 1991) modulated by phosphorylation . Future work will have to clarify the functional role of V ASP phosphorylation and the physiological significance of the specific association of V ASP with actin filaments and focal contact areas.
Materials and methods
Cells
Human dermal fibroblasts, kindly provided by Dr Hiihn (Department of Human Genetics, University of Wiirzburg, FRG), were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL, Eggenstein, FRG) supplemented with 10% fetal calf serum (FCS, Gibco BRL) and used as passages 7 -12 for experiments. Rat muscle fibroblasts (Schulze et al., 1989) and chicken embryo fibroblasts (Westmeyer et al., 1990) were cultured as described. BHK and PtK2 cells were cultured in DMEM supplemented with 10% FCS. LLC-PKI cells were grown in minimal essential medium (MEM, Gibco BRL) supplemented with 7.5% FCS. Culture media were supplemented with I % antibiotic-antimycotic solution (Sigma, Deisenhofen, FRG). All cells were cultured at 3rC with 5 % CO 2 ,
Experiments with fibroblasts
Human dermal fibroblasts were grown for 2 -3 days in 58 x 15 mm tissue culture dishes (Nunc, Wiesbaden-Biebrich, FRG) until they reached a density of 0.7 -2.0 x 10 4 cells/cm 2 For immunofluorescence analysis, cells were grown in parallel on coverslips. One hour prior to experiments, cells were incubated with a medium containing 10 JLM indomethacin in order to inhibit endogenous prostaglandin synthesis . Cells were incubated at 3rC with 5 JLM PG-El (Sigma) and/or 470 JLM 8-pCPT-cGMP (BioLog, Bremen, FRG) for 5 min or 30 min, respectively . Agents examined were added to the cells in phosphate buffered saline (PBS, 10 mM sodium phosphate pH 7 .4, 150 mM NaCI) supplemented with 1 mM CaCI 2 , 2 mM MgCI2 and 10 JLM indomethacin. Cells incubated with the vehicle medium alone were used as controls. At the end of incubations, cells were lysed in SDS sample buffer or fixed for immunofluorescence as indicated below. Antiserum M4 rabbit antiserum against human V ASP was raised as described previously (Halbtiigge et al. , 1990) . Affinity-purified M4 was prepared by adsorption and elution of antibodies using protein antigens immobilized on nitrocellulose blots essentially as described (Smith and Fisher, 1984) . In short, antiserum M4 (600 JLI , diluted I: 10 in PBS, 0.5% Tween 20) was adsorbed to the 46/50 kDa area of a nitrocellulose sheet to which platelet homogenate proteins (I. I mg) separated by SDS -PAGE had been transferred . Antibodies were eluted from nitrocellulose strips by three successive 30 s washes (1.5 ml each) with glycine-HCI buffer, pH 2.3. This eluate, which was immediately neutralized by the addition of 0.25 vol of 250 mM sodium phosphate, is referred to as 'affinity-purified M4 '. An aliquot of affinity-purified M4 (37 JLI), diluted 1:60 in buffer A (PBS, 0 .5% Tween 20, lOO JLg/ml BSA , 0 .01 % NaN 3 ), was successively preadsorbed to the 46/50 kDa area of four different nitrocellulose blots of platelet homogenate proteins (2.3 mg per sheet) for several hours each. This solution depleted of VASP antibodies was used for control immunofluorescence and immunoblot experiments.
Fluorescent staining of cells Cells grown on coverslips were fixed in 3.7% formaldehyde for 20 min on ice, perrneabilized by 0.2% Triton X-lOO in PBS for 10 min and incubated for 30 min at room temperature with M4 (diluted 1:500 in PBS) or affinitypurified M4 (diluted 1:60 in buffer A). Affinity-purified M4 , preadsorbed as described above, was used without further dilution. Subsequently, cells were incubated for 30 min at room temperature with 4.3 JLg/m1 rhodamineconjugated affinity-purified donkey anti-rabbit IgG (Dianova, Hamburg, FRG) and, where indicated, with -0.33 JLM NBD-phallacidin (Molecular Probes, Eugene, OR, USA). Cells were washed repeatedly with PBS between individual incubation steps.
For immunofluorescence studies with platelets, venous blood from healthy volunteers was collected into 5 mI coagulation tubes (Monovette SNC; Sarstedt, Miimbrecht, FRG) and centrifuged for 15 min at 360 g. The supematant (platelet rich plasma) was placed onto ethanol-cleaned glass coverslips (Superior, Bad Mergentheim, FRG). Platelets were allowed to settle and spread for 30-40 min in a moist chamber at room temperature. Platelets not attached were removed by rinsing the covers lips twice with PBS. In some cases, platelet rich plasma was diluted I :20 with HEPES buffer (10 mM HEPES pH 7.4, 145 mM NaCI, 5 mM KCI , 1 mM MgCI2' 10 mM glucose) and coverslips were rinsed twice and incubated for 5 min at 37°C in the same buffer prior to fixation. Spread platelets were fixed and perrneabilized by sequential incubation with 3.7 % formaldehyde in PBS for 10 min on ice and acetone for 10 min at -20°C, with PBS washings between incubations. Subsequent processing of all platelet samples was then identical to that described above for tissue culture cells.
All specimens were examined with Leitz Aristoplan or Zeiss Axiophot microscopes equipped with epifluorescence optics. Photographs were taken with Tri-X Pan 400 (Kodak) .
Protein associated with actin filaments and focal contacts
Immunoblotting Samples were separated by SDS-PAGE using 3% stacking and 8% separating gels. Proteins were electrophoretically transferred to nitrocellulose (0.45 JLm , Schleicher & Schuell, Dassel, FRG) for 1.5 -3.0 h at 3 -4 V Icm in a buffer containing 25 mM Tris (pH 10), 192 mM glycine and 20% methanol. Nitrocellulose sheets were blocked for 6 h or ovemight in blocking medium (PBS, 1 % haemoglobin, 0.3% Triton X-lOO, 0.05 % Tween 20, 0.01 % NaN 3 ) , incubated for 1.5 h at room temperature with antiserum M4 (1: 1500 in b-Iocking medium) or affinity-purified M4 with or without prior preadsorption. For use in immunoblots, affinity-purified M4 and preadsorbed affinity-purified M4 were applied at identical final dilutions (1: 120 in buffer A). Antibodies bound to immobilized proteins were detected by incubation with 0.1 JLCi/ml [ 125 I]protein A (>30 mCi/mg ; Amersham Buchler, Braunschweig, FRG) . Following the incubations with antiserum and [ 125 I]protein A, nitrocellulose sheets were washed repeatedly with PBS supplemented with 0.3% Triton X-lOO and 0.05% Tween 20. Immunoreactivity was detected by autoradiography of nitrocellulose blots.
Protein purification VASP was purified as described previously (Halbtiigge and Waiter, 1989) except that Q-Sepharose FF chromatography was performed at pH 7.5 and the CM-cellulose chromatography step was omitted. Protein concentrations were determined using the Bradford reagent for purified V ASP and the Lowry reagent for cell homogenates with BSA as a standard. Actin was purified from porcine skeletal muscle acetone powder essentially as described (Jockusch and Isenberg, 1981) . Actin concentration was calculated from the absorbance at 290 nm (Gordon et al., 1976) .
Cosedimentation assay G-Actin (I mg/ml) was allowed to polymerize for 30 min at room temperature by the addition of 2 mM MgCI2 and 20 mM KCI (final concentrations). VASP was centrifuged at 195000 g for 3 h at 4° C in order to remove insoluble particles. After a 30 min co-incubation of F-actin and VASP at room temperature (500 JLg/ml actin, 110 JLg/ml V ASP) in an imidazole buffer (5 mM imidazole, I mM Tris-HCI [pH 7.2]; 60 mM KCI; 2 mM MgCI 2 ; 0.1 mM CaCI 2 ; 1.25 mM EGTA; 0.35 mM ATP; 0.5 mM DTE), the assay mixture was centrifuged at lOO 000 g for 2 h at room temperature in Ultra-Clear tubes (Beckman, Frankfurt, FRG) coated with 5 % BSA. Control sedirnentations were performed in which either V ASP or actin were omitted . Supematants were carefully aspirated, pellets were resuspended in the original assay volume, and equal aliquots of both the supernatants and resuspended pellets were then analysed by SDS -PAGE.
